TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Albumin-corrected Serum Calcium From Baseline to Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in 24-hour Urinary Calcium Excretion From Baseline to Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in 24-hour Urinary Calcium:Creatinine Ratio From Baseline to Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase of Interferon Gamma Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Symptoms Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Rating Scale for Depression-17 Item
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Complete Clearance of Treated Warts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Subjects With Any Solicited General Adverse Events (AEs) After the First Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Any Solicited General Adverse Events (AEs) After the Second Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Transfusion Requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Relief of dysphagia measured by dysphagia scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival time from the interventional procedure to the last follow-up
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of days of hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change from baseline perceived stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: degrees of maximum active flexion at the distal interphalangeal joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percent Predicted Slow Vital Capacity (SVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of functional discomfort following intralesional bevacizumab injection
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Function and phenotype of HER2-specific TE cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensitivity of Tozuleristide compared to Surgeon Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of Tozuleristide compared to Surgeon Specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with clinically significant acute GHVD (Grade II or higher)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of HPV detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percent change in MRI metrics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intrinsic diagnostic qualities of digital dPCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ICP Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: LS mean difference of LPS from placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LS mean difference of WASO from placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of pulmonary vein isolation (PVI) gaps per vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentages Of Subjects Who Achieved HI Titer ≥40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentages Of Subjects Who Achieved Seroconversion Or Significant Increase In HI Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Ratio of Subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Completing at Least 80% of the Targeted Sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Total Score of the Brief International Assessment of Cognition in MS (BICAMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of subjects continuing participation in SMS service
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of subject responses to SMS requests
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Dark Adaptation Rod Intercept Time (RIT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Volume of local anesthetics used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical performance according to FDI criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical performance according to USPHS criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients With ≥50% Seizure Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: LDL density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in microvascular perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of treated and cured DU participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of satisfaction with the program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Variation of the mean Pressure Pain Thresholds (PPTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of articular surface reduction grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Skin to skin duration of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Overall Aesthetic Improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in aortic distensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the LV volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the LV pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Muscle protein fractional synthetic rate (FSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of ultrasound guided axillary brachial plexus block techniques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cognitive functioning (TMT-A)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive functioning (TMT-B)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Daily overall pain level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain in the low back
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain in the lower extremities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Response at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cutaneous sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Gait and balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: macular thickness changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of HemoglobinA1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Retrobulbar Arteries Doppler Waveform
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical cure in the worse eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective Rate of Patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in infant colic severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean antiHAV and antiHBV Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vascular Ingrowth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Proximal femoral fracture outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 30 Day Readmissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Correlation of depth of invasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute hypercapnic respiratory failure episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Development of diverticulosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area under the dermal concentration time curve for prilocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood lidocaine concentrations versus time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood prilocaine concentrations versus time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of Hepatocellular Carcinoma (HCC)
Endpoint domain: Mortality/survival
Primary endpoint: Number of subjects reporting overall liking of drug formulation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in therapeutic alliance from baseline to 12 weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Adiposity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Effectiveness of the Treatment Using the Galderma Chin Restrusion Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Tinnitus Handicap Inventory
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of Tinnitus Numeric Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change Clinical Global Impression
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of high grade treatment-related select adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of high grade immune-mediated adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of ureteric injuries
Endpoint domain: Adverse events/effects
Primary endpoint: level of CD11a in patients with ITP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Voice Quality
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduced measured workplace chemicals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of Pseudomonas cross infections
Endpoint domain: Adverse events/effects
Primary endpoint: Annual direct medical cost for on-demand strategy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Annual direct medical cost for secondary prophylaxis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Device or Procedure Related AV Block Persistent Through Discharge From Hospital
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HDL particles size and number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients requiring mechanical ventilation and/or deceased by Day 60
Endpoint domain: Mortality/survival
Primary endpoint: Complete response of RINV
Endpoint domain: Adverse events/effects
Primary endpoint: Myocardial Extracellular Volume (ECV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Discoloration/Staining potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical tumor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Symptom Burden Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in 8-oxo-dG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events related to the infusion of cells
Endpoint domain: Adverse events/effects
Primary endpoint: Professionals' experience in implementing DT
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Visual Analogue Scale for Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in The Fatigue Severity Scale (FSS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Composite Brief Assessment of Cognition (BAC) Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Full aneurysm occlusion within 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rate of ipsilateral palpable groin hematomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: FFR Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants infected with Covid-19
Endpoint domain: Adverse events/effects
Primary endpoint: Confirmed Virologic Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Childhood Autism Rating Scales-2 (CARS-2)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: occurrence of chronic GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Pathologic complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Tumors size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in Tumors lesions numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in Tumors lesions SUVmax (FDG-Maximum Standardized Uptake Values)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mite density in skin surface biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in ophthalmic evaluations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating endothelial cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceleration of gastrointestinal recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Survivorship of ProFemur Z Stem
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of procedure related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Volume-rendered 3D-CT images measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for detecting ischemic heart disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Beta electroencephalographic (EEG) activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Theta electroencephalographic (EEG) activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Liver Echogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver Enzymes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial glucagon area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Displacement of Amyloid beta oligomers into cerebrospinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Level of knowledge about prenatal screening and diagnostic testing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Good Drug Effects
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cmax: Maximum Observed Plasma Concentration for Ixazomib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Ixazomib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Ixazomib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Constipation symptoms score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Post-operative Radiographic Measurements of Prosthetic Relationships
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Radiographic Analysis for Lucent Lines and Prosthesis Loosening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: number of red blood cells transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: RBC deformability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy of air test in detecting postoperative atelectasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in communication skills ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in professionalism behaviors ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ICD shock for any cause
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Days Abstinent (PDA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in genomic alterations of PC driver genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oxyhemoglobin desaturation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Tolerance of Oral Nutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Total Neuropathy Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Variation of Flow mediated dilation percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of endothelial progenitor cells (EPC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HIV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: development of brain atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: progression of disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Dose-limiting toxicities of JWCAR029
Endpoint domain: Adverse events/effects
Primary endpoint: Short-term energy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Adolescents Diagnosed With Depression Seen in Well Child Visits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Elevated Blood Pressure Measured and Appropriately Acted on by Providers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Patients With Abnormal Laboratory Results With Appropriate Actions Without Delay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol and Substance-use Frequency Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Firsthand Alcohol-Related Harms
Endpoint domain: Adverse events/effects
Primary endpoint: Secondhand Alcohol-Related Harms
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom from genito-urinary injury/trauma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Knowledge of paediatricians regarding early childhood caries
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Practice of paediatricians regarding early childhood caries
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Attitude of paediatricians regarding early childhood caries
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Presence of pancreatic cyst
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: cardiopulmonary function changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intensity of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion relapse-free at three years
Endpoint domain: Mortality/survival
Primary endpoint: Changes in proteinuria levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: VAS scores after surgery
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Proportion of Patients Who do Not Demonstrate Disease Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes